HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

Retrovirology

Volumn 8, Issue , 2011, Pages

  Fun, Axel ^a   Van Maarseveen, Noortje M ^a   Pokorná, Jana ^b   Maas, Renée E M ^a   Schipper, Pauline J ^a   Konvalinka, Jan ^b   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BEVIRIMAT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROTEIN VP2; 3-O-(3',3'-DIMETHYLSUCCINYL)BETULINIC ACID; GAG PROTEIN; GAG PROTEIN P1, HUMAN IMMUNODEFICIENCY VIRUS; SUCCINIC ACID DERIVATIVE; TRITERPENE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PROTEIN CLEAVAGE; VIRUS REPLICATION; WILD TYPE; CELL LINE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; PHYSIOLOGY; VIROLOGY; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; SUCCINATES; TRITERPENES; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 80052028225     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-70     Document Type: Article

References (37)

1. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72:7632-7637. 110025, 9696866.
2. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007, 4:e36. 10.1371/journal.pmed.0040036, 1769415, 17227139.
3. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 2006, 11:879-887.
4. Nijhuis M, van Maarseveen NM, Verheyen J, Boucher CA. Novel mechanisms of HIV protease inhibitor resistance. Curr Opin HIV AIDS 2008, 3:627-632. 10.1097/COH.0b013e3283136cd9, 19373034.
5. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009, 5:e1000345. 10.1371/journal.ppat.1000345, 2652074, 19300491.
6. Kilgore NR, Reddick M, Zuiderhof M, Stanley D, Nitz T, Bullock P, Allaway GP, Martin DE. Characterization of PA1050040, a second-generation HIV-1 maturation inhibitor. IAS 2007, 4th IAS Conference On HIV Pathogenesis, Treatment and Prevention, Sydney, Australia 2007, Abstract MOPDX05.
7. Beelen AP, Otto J, Fidler M, Sanguinetti E, Smiley P, Balch A, Medlock M, Jackson M, Swabb EA. Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects. Program & Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada 2009, Abstract 570.
8. Baichwal V, Austin H, Brown B, McKinnon R, Yager K, Kumar V, Gerrish D, Anderson M, Carlson R. Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055. Program & Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada 2009, Abstract 561.
9. Kumar V, Gerrish D, Hoarau C, Yager K, Austin H, McKinnon R, Brown B, Baichwal V, Papac D, Bradford C, Patton S, Bulka K, DeMie L, Carlson R. Next Generation Orally Bioavailable HIV-1 Maturation Inhibitors. 239th ACS National Meeting & Exposition, San Francisco, USA, March 2010, Abstract 1371.
10. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, Murray E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother 2009, 53:5080-5087. 10.1128/AAC.00759-09, 2786326, 19805571.
11. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 2007, 373:355-366. 10.1016/j.jmb.2007.07.070, 2066180, 17826792.
12. Braun K, Frank M, Pipkorn R, Reed J, Spring H, Debus J, Didinger B, von der Lieth CW, Wiessler M, Waldeck W. HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytes. Int J Med Sci 2008, 5:230-239. 2500149, 18695744.
13. Titolo S, Mercier JF, Wardrop E, Schwedler U, Goudreau N, Lemke C, Faucher AM, Yoakim C, Simoneau B, Sundquist WI, Mason S. Discovery of Potent HIV-1 CapsidAssembly Inhibitors. Program & Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA 2010, Abstract 50.
14. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003, 100:13555-13560. 10.1073/pnas.2234683100, 263852, 14573704.
15. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006, 80:10957-10971. 10.1128/JVI.01369-06, 1642185, 16956950.
16. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol 2011, 85:1420-1428. 10.1128/JVI.01926-10, 3028903, 21106735.
17. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan PR, Martin DE, Salzwedel K, Allaway GP. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther 2008, 13.
18. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother 2009, 53:2185-2188. 10.1128/AAC.01650-08, 2681549, 19223634.
19. Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. Aids 2009, 24:669-673.
20. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009, 83:4884-4894. 10.1128/JVI.02659-08, 2682084, 19279107.
21. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997, 71:6662-6670. 191944, 9261388.
22. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. Aids 1999, 13:2349-2359. 10.1097/00002030-199912030-00006, 10597776.
23. Cote HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001, 75:589-594. 10.1128/JVI.75.2.589-594.2001, 113954, 11134271.
24. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004, 78:922-929. 10.1128/JVI.78.2.922-929.2004, 368845, 14694123.
25. Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology 2010, 7:36. 10.1186/1742-4690-7-36, 2873507, 20406463.
26. Knapp DJ, Harrigan PR, Poon AF, Brumme ZL, Brockman M, Cheung PK. In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by "Deep" Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1. J Clin Microbiol 2011, 49:201-208. 10.1128/JCM.01868-10, 3020451, 21084518.
27. Margot NA, Gibbs CS, Miller MD. Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat. Antimicrob Agents Chemother 2010, 54:2345-2353. 10.1128/AAC.01784-09, 2876391, 20308382.
28. van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007, 195:399-409. 10.1086/510533, 17205479.
29. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000, 74:8524-8531. 10.1128/JVI.74.18.8524-8531.2000, 116364, 10954553.
30. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J Virol 2002, 76:8659-8666. 10.1128/JVI.76.17.8659-8666.2002, 136408, 12163585.
31. Gonzalez LM, Brindeiro RM, Aguiar RS, Pereira HS, Abreu CM, Soares MA, Tanuri A. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004, 48:3552-3555. 10.1128/AAC.48.9.3552-3555.2004, 514783, 15328124.
32. Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, Vandamme AM. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods 2006, 132:181-186. 10.1016/j.jviromet.2005.10.008, 16271771.
33. van Maarseveen NM, Huigen MC, de Jong D, Smits AM, Boucher CA, Nijhuis M. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods 2006, 133:185-194. 10.1016/j.jviromet.2005.11.008, 16368153.
34. van Maarseveen NM, de Jong D, Boucher CA, Nijhuis M. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr 2006, 42:162-168. 10.1097/01.qai.0000219787.65915.56, 16645546.
35. Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996, 40:2404-2409. 163542, 8891152.
36. Kozisek M, Saskova KG, Rezacova P, Brynda J, van Maarseveen NM, De Jong D, Boucher CA, Kagan RM, Nijhuis M, Konvalinka J. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J Virol 2008, 82:5869-5878. 10.1128/JVI.02325-07, 2395164, 18400858.
37. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010, 18:156-163.